Authors
Jiro Tashiro, Tomoko Warita, Katsuhiko Warita
Published in
Journal of pharmacological sciences. Volume 162. Issue 4. Pages 268-280. Epub Sep 26, 2026.
Abstract
Non-small-cell lung cancer (NSCLC) is a major type of lung cancer, accounting for 85% of lung cancer cases. Statins are cholesterol-lowering drugs that exert anticancer effects by inhibiting HMG-CoA reductase (HMGCR), a rate-limiting enzyme in the mevalonate pathway, in multiple cancer types, including NSCLC. However, statin sensitivity varies among cancer cells, highlighting the need to identify the determinants of this variability. High basal expression and statin-induced upregulation of mevalonate pathway enzymes, including HMGCR, are associated with statin resistance in cancer cells. Given that the expression of mevalonate pathway enzymes is regulated by cholesterol, intracellular cholesterol status may influence statin sensitivity. Here, we demonstrated that cholesterol supplementation enhanced the growth-inhibitory effects of atorvastatin in NSCLC cells with an increase in fluorescence intensity of filipin, which binds to free cholesterol. In contrast, methyl-β-cyclodextrin, a cholesterol-depleting agent, attenuated the effects of atorvastatin with a slight decrease in filipin intensity. In addition, oxysterols, which are oxidized derivatives of cholesterol, enhanced the effects of atorvastatin without increasing the filipin intensity. Furthermore, the lysosomal cholesterol transport inhibitor U18666A attenuated the effects of atorvastatin, with an increase in filipin intensity. Our data suggested that quantitative and qualitative intracellular cholesterol status may regulate statin sensitivity in NSCLC cells.
PMID:
43020531
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0